cn-105
Peptideexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02670824)
Timeline
Indications
Mechanism of action
- Apolipoprotein EINHIBITOR
APOE inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C- Mol. weight
- 713.85 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314912 ↗
Also known as
- cn-105
- cn-105
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06255977 | Phase 2 | Aug 24, 2022 | Capital Medical University |
| NCT03802396 | Phase 2 | Apr 17, 2019 | Duke University |
| NCT03168581 | Phase 2 | Jun 1, 2017 | AegisCN LLC, Duke University, PharPoint Research, Inc. |
| NCT02670824 | Phase 1 | Dec 1, 2015 | AegisCN LLC |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AegisCN LLC | For profit | 2 | 2 | 2 | 2015 |
| Duke University | Academic/Hospital | 2 | 1 | 1 | 2017 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| PharPoint Research, Inc. | For profit | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1